The Evolving Landscape of Biliary Tract Cancers
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: An Overview on Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Mark Yarchoan, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.
EP. 2: Incidence and Risk Factors for Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.
EP. 3: Challenges in Diagnosing Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.
EP. 4: Biliary Tract Cancers: Staging and Clinicopathologic Features By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.
EP. 5: Guidelines for Molecular Testing in Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.
EP. 6: Treatment Options for Early-Stage Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.
EP. 7: What is the Role of Transplant in Early-Stage Biliary Tract Cancers? By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.
EP. 8: Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.
EP. 9: An Overview of Systemic Therapy for Advanced Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.
EP. 10: Advanced Biliary Tract Cancers: First- and Second-Line Chemotherapy By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.
EP. 11: TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
EP. 12: Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.
EP. 13: Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse Events By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
EP. 14: Sequencing Therapy in Patients With Advanced Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.
EP. 15: Novel Agents Being Explored in Advanced Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.
EP. 16: Advanced Biliary Tract Cancers: Novel Biomarker Strategies By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Aiwu Ruth He, MD, PhD, Anjana Pillai, MD, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University, Mark Yarchoan, MD Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
